Martina Flammer - May 28, 2024 Form 4 Insider Report for INSMED Inc (INSM)

Role
Chief Medical Officer
Signature
/s/ Martina Flammer, M.D., by Michael A. Smith as Attorney-in-fact
Stock symbol
INSM
Transactions as of
May 28, 2024
Transactions value $
-$3,357,148
Form type
4
Date filed
5/30/2024, 05:43 PM
Previous filing
May 17, 2024
Next filing
Jun 12, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction INSM Common Stock Options Exercise $2.46M +104K +97.81% $23.66 210K May 28, 2024 Direct F1
transaction INSM Common Stock Sale -$5.15M -104K -49.45% $49.62 106K May 28, 2024 Direct F1, F2
transaction INSM Common Stock Options Exercise $503K +21.2K +19.97% $23.75 127K May 30, 2024 Direct F1
transaction INSM Common Stock Sale -$1.17M -21.2K -16.65% $55.00 106K May 30, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction INSM Stock Option (right to buy) Options Exercise $0 -104K -84.62% $0.00 18.9K May 28, 2024 Common Stock 104K $23.66 Direct F1, F3
transaction INSM Stock Option (right to buy) Options Exercise $0 -21.2K -37.5% $0.00 35.3K May 30, 2024 Common Stock 21.2K $23.75 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
F2 This is the weighted average sales price representing 103,806 shares sold at prices ranging from $49.53 to $50.00 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
F3 The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. All options are currently exercisable.